-
公开(公告)号：US10111881B2
公开(公告)日：2018-10-30
申请号：US15479032
申请日：2017-04-04
IPC分类号： A61K31/5377 , A61P31/12 , A61K31/4155 , C07D409/14 , C07D413/12
摘要： Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.
-
公开(公告)号：US09222142B2
公开(公告)日：2015-12-29
申请号：US14233710
申请日：2014-01-15
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , TEXAS BIOMEDICAL RESEARCH INSTITUTE , THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE
IPC分类号： C12Q1/70 , C07K14/075 , C12N15/861 , G01N33/569 , C12N7/00 , C12N15/86 , C07K14/005 , C07K16/08 , C12Q1/68 , A61K39/00
CPC分类号： C12Q1/701 , A61K2039/55566 , C07K14/005 , C07K14/075 , C07K16/081 , C07K2317/76 , C12N7/00 , C12N15/86 , C12N15/861 , C12N2710/10321 , C12N2710/10343 , C12Q1/68 , C12Q1/702 , C12Q2563/131 , C12Q2600/156 , G01N33/56983
摘要： Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are described herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are described. Methods are described for detecting BaAdV-2/4 and BaAdV-3. Methods are also described for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.
摘要翻译： 狒狒腺病毒（BaAdV）-2/4和BaAdV-3在本文中描述。 描述了BaAdV-2/4和BaAdV-3多核苷酸，特异性结合BaAdV-2/4和/或BaAdV-3的多肽和抗体。 描述了用于检测BaAdV-2/4和BaAdV-3的方法。 还描述了治疗，预防和诱导对BaAdV-2/4和/或BaAdV-3的免疫应答的方法。 还提供套件。
-
公开(公告)号：US20220409602A1
公开(公告)日：2022-12-29
申请号：US17840563
申请日：2022-06-14
发明人： Marcel M. Daadi
IPC分类号： A61K31/4535 , A61P25/14
摘要： Provided here are arylpiperazine pharmacophore compositions that mitigate levodopa-induced dyskinesia and significantly improve Parkinson's disease-like symptoms. These dopamine D3 receptor ligands have high affinity and selectivity, are orally active, and have desirable drug-like properties.
-
公开(公告)号：US20220387520A1
公开(公告)日：2022-12-08
申请号：US17755008
申请日：2020-10-19
发明人： Russell AULT , Niannian JI , Juan I. MOLIVA , Robert SVATEK , Jordi B. TORRELLES
摘要： Provided are methods for treatment of bladder cancer using compositions of modified Mycobacterium bovis Bacillus Calmette et Guerin (BCG). Also, provided are methods of treatment of non-muscle invasive bladder cancer by intra-bladder injection of these modified BCG compositions. Also, provided are methods of treatment of muscle-invasive bladder cancer by intra-tumor injection of these modified BCG compositions.
-
公开(公告)号：US10125173B2
公开(公告)日：2018-11-13
申请号：US15094860
申请日：2016-04-08
发明人： Ruth M. Ruprecht , Michael Humbert
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00 , A61K39/12 , C07K14/005 , A61K39/21 , C07K16/10 , C07K16/42 , C12N7/00 , A61K38/00
摘要： The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).
-
公开(公告)号：US20180161333A1
公开(公告)日：2018-06-14
申请号：US15479032
申请日：2017-04-04
IPC分类号： A61K31/5377 , A61K31/4155 , A61P31/12 , C07D413/12 , C07D409/14
CPC分类号： A61K31/5377 , A61K31/4155 , A61P31/12 , C07D409/14 , C07D413/12
摘要： Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.
-
7.发明申请公开(公告)号：US20140178426A1
公开(公告)日：2014-06-26
申请号：US14062125
申请日：2013-10-24
IPC分类号： A61K39/21
CPC分类号： A61K39/12 , A61K2039/523 , A61K2039/5256 , A61K2039/53 , A61K2039/55566 , C12N15/00 , C12N15/86 , C12N2740/15034 , C12N2740/15041
摘要： The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
摘要翻译： 本发明提供了使用含有分化特异性转录调节元件的载体将干扰细胞感兴趣的基因的新型组合物和方法。 例如，可以用疫苗构建体转染内部上皮细胞，其具有驱动病毒包膜蛋白表达的上皮细胞分化特异性启动子。 当所使用的启动子对终末分化的上皮细胞是特异性的，则病毒包膜蛋白将仅在上皮的上部表达，因此刺激免疫应答。 基底层中感染的上皮干细胞将继续产生新的抗原表达细胞，而不被免疫应答所消除。 本发明可用于开发靶向内部粘膜如HIV的病毒剂的疫苗。
-
公开(公告)号：US20220315900A1
公开(公告)日：2022-10-06
申请号：US17657344
申请日：2022-03-30
IPC分类号： C12N5/071
摘要： Provided here methods of generating human alveolar macrophage-like cells in-vitro from blood-derived monocytes by culturing them in a cell culture medium containing a mixture of a surfactant and two or more cytokines. This mixture can contain calfactant, granulocyte-macrophage colony-stimulating factor, transforming growth factor beta, and interleukin-10.
-
公开(公告)号：US10751406B2
公开(公告)日：2020-08-25
申请号：US15672108
申请日：2017-08-08
摘要： The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
-
公开(公告)号：US20200093916A1
公开(公告)日：2020-03-26
申请号：US16348104
申请日：2017-11-07
IPC分类号： A61K39/21 , C12N7/00 , A01K67/027
摘要： Provided here are certain recombinant HIV compositions and animal models to evaluate prophylactic and therapeutic antiviral compositions.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.025 秒)
